Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887492 · ClinicalTrials.gov registry record · Phase 1
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Tango Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 13
- Study locations
NCT05887492 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 126 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower). The trial reports 13 study locations across 9 states.
The verdict
NCT05887492, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Tango Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG TNG260
Study Locations (13)
Michigan
- Henry Ford Health System - Detroit
- START MidWest - Grand Rapids
New York
- NYU Langone Hematology Oncology Associates-Mineola - Mineola
- New York University Langone Health - New York
Texas
- US Oncology Investigational Products Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology Virginia - Fairfax
- US Oncology Investigational Products Center - Norfolk
California
- UCLA Hematology/Oncology - Santa Monica
Colorado
- SCRI at HealthOne - Denver
Florida
- Florida Cancer Specialists - Sarasota
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05887492
The ClinicalTrials.gov registry entry for NCT05887492 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower). The listed sponsor is Tango Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05887492 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Michigan, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05887492 about?
NCT05887492 is a clinical study titled "Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors". The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safe...
What is the current status of trial NCT05887492?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2023-06-12. Estimated completion is 2026-06.
What conditions does trial NCT05887492 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Lung Adenocarcinoma, Solid Tumors, Adult.
What interventions are being tested in trial NCT05887492?
The interventions under investigation include: Pembrolizumab (DRUG), TNG260 (DRUG).
Who is sponsoring clinical trial NCT05887492?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887492 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.